Actarit - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 70

<< First< Prev

Page of 4

Next >Last >>

Select item 110539561.

Ionic Liquid Transdermal Patches of Two Active Ingredients Based on Semi-Ionic Hydrogen Bonding for Rheumatoid Arthritis Treatment

Faxing Zhang, Lu Li, Xinyuan Zhang, Hongyu Yang, Yingzhen Fan, Jian Zhang, Ting Fang, Yaming Liu, Zhihao Nie, Dongkai Wang

Pharmaceutics. 2024 Apr; 16(4): 480. Published online 2024 Apr 1. doi: 10.3390/pharmaceutics16040480

PMCID:: PMC11053956

Article PDF–5.0M

Select item 76991992.

Identification and Validation of Carbonic Anhydrase II as the First Target of the Anti-Inflammatory Drug Actarit

Ghita Ghislat, Taufiq Rahman, Pedro J. Ballester

Biomolecules. 2020 Nov; 10(11): 1570. Published online 2020 Nov 19. doi: 10.3390/biom10111570

PMCID:: PMC7699199

Article PDF–1.2M

Select item 31789733.

Determination of Actarit from Human Plasma for Bioequivalence Studies

P. Loya, M. N. Saraf

Indian J Pharm Sci. 2010 Nov-Dec; 72(6): 726–731. doi: 10.4103/0250-474X.84581

PMCID:: PMC3178973

Article PDF–534K

Select item 70321934.

Double-layered osmotic pump controlled release tablets of actarit: In vitro and in vivo evaluation

Yuenan Li, Hao Pan, Hongliang Duan, Jianting Chen, Zhihong Zhu, Jingxin Fan, Pingfei Li, Xinggang Yang, Weisan Pan

Asian J Pharm Sci. 2019 May; 14(3): 340–348. Published online 2018 Aug 19. doi: 10.1016/j.ajps.2018.05.009

PMCID:: PMC7032193

Article PDF–1.8M

Select item 57614805.

Stability-indicating assay method for determination of actarit, its process related impurities and degradation products: Insight into stability profile and degradation pathways^☆

A. Abiramasundari, Rahul P. Joshi, Hitesh B. Jalani, Jayesh A. Sharma, Dhaivat H. Pandya, Amit N. Pandya, Vasudevan Sudarsanam, Kamala K. Vasu

J Pharm Anal. 2014 Dec; 4(6): 374–383. Published online 2014 Jan 25. doi: 10.1016/j.jpha.2014.01.002

PMCID:: PMC5761480

Article PDF–1.3M

Select item 57911296.

Lipid-Based Nanoparticles as a Potential Delivery Approach in the Treatment of Rheumatoid Arthritis

Shih-Yi Chuang, Chih-Hung Lin, Tse-Hung Huang, Jia-You Fang

Nanomaterials (Basel) 2018 Jan; 8(1): 42. Published online 2018 Jan 15. doi: 10.3390/nano8010042

PMCID:: PMC5791129

Article PDF–1.3M

Select item 99269907.

Identification and Validation of Immune-Related Genes Diagnostic for Progression of Atherosclerosis and Diabetes

Yajuan Fu, Lingbo Xu, Hui Zhang, Ning Ding, Juan Zhang, Shengchao Ma, Anning Yang, Yinjv Hao, Yujing Gao, Yideng Jiang

J Inflamm Res. 2023; 16: 505–521. Published online 2023 Feb 10. doi: 10.2147/JIR.S393788

PMCID:: PMC9926990

Article PDF–14M

Select item 79213398.

Emphysematous cystitis in a patient using immunosuppressant agents

Daiki Yokokawa, Takanori Uehara, Masatomi Ikusaka

J Gen Fam Med. 2021 Mar; 22(2): 92–93. Published online 2020 Nov 7. doi: 10.1002/jgf2.399

PMCID:: PMC7921339

Article PDF–229K

Select item 94006449.

Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment

Simran Nasra, Dhiraj Bhatia, Ashutosh Kumar

Nanoscale Adv. 2022 Aug 23; 4(17): 3479–3494. Published online 2022 Jul 26. doi: 10.1039/d2na00229a

PMCID:: PMC9400644

Article PDF–1.1M

Select item 851384910.

Potential application of measuring serum infliximab levels in rheumatoid arthritis management: A retrospective study based on KURAMA cohort data

Kazuto Nakae, Sho Masui, Atsushi Yonezawa, Motomu Hashimoto, Ryu Watanabe, Koichi Murata, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Kotoko Yokoyama, Noriko Iwamoto, Takashi Shimada, Miyuki Nakamura, Masaya Denda, Kotaro Itohara, Shunsaku Nakagawa, Yasuaki Ikemi, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Kazuo Matsubara

PLoS One. 2021; 16(10): e0258601. Published online 2021 Oct 13. doi: 10.1371/journal.pone.0258601

PMCID:: PMC8513849

Article PDF–1.4M

Select item 710401211.

Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights

Kumar Janakiraman, Venkateshwaran Krishnaswami, Vijaya Rajendran, Subramanian Natesan, Ruckmani Kandasamy

Mater Today Commun. 2018 Dec; 17: 200–213. Published online 2018 Sep 15. doi: 10.1016/j.mtcomm.2018.09.011

PMCID:: PMC7104012

Article PDF–1.1M

Select item 697057412.

Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery

Disha Kesharwani, Rishi Paliwal, Trilochan Satapathy, Swarnali Das Paul

J Pharmacopuncture. 2019 Dec; 22(4): 210–224. Published online 2019 Dec 31. doi: 10.3831/KPI.2019.22.029

PMCID:: PMC6970574

Article PDF–1.2M

Select item 1072560913.

Landscape of molecular crosstalk between SARS-CoV-2 infection and cardiovascular diseases: emphasis on mitochondrial dysfunction and immune-inflammation

Shiyu Dai, Ting Cao, Han Shen, Xuejing Zong, Wenyu Gu, Hanghang Li, Lei Wei, Haoyue Huang, Yunsheng Yu, Yihuan Chen, Wenxue Ye, Fei Hua, Hongyou Fan, Zhenya Shen

J Transl Med. 2023; 21: 915. Published online 2023 Dec 16. doi: 10.1186/s12967-023-04787-z

PMCID:: PMC10725609

Article PDF–6.8M

Select item 1013210614.

Catalytic utilization of converter gas – an industrial waste for the synthesis of pharmaceuticals

Sofiya A. Runikhina, Oleg I. Afanasyev, Ekaterina A. Kuchuk, Dmitry S. Perekalin, Rajenahally V. Jagadeesh, Matthias Beller, Denis Chusov

Chem Sci. 2023 Apr 26; 14(16): 4346–4350. Published online 2023 Mar 31. doi: 10.1039/d3sc00257h

PMCID:: PMC10132106

Article PDF–832K

Select item 750464815.

Hepatitis E Virus and rheumatic diseases: what do rheumatologists need to know?

Salvatore Di Bartolomeo, Francesco Carubbi, Paola Cipriani

BMC Rheumatol. 2020; 4: 51. Published online 2020 Sep 21. doi: 10.1186/s41927-020-00149-0

PMCID:: PMC7504648

Article PDF–1.0M

Select item 1096338416.

Exosomes and exosomal miRNAs: A new avenue for the future treatment of rheumatoid arthritis

Yuan Liu, Ping Jiang, Yuan Qu, Chuanguo Liu, Di Zhang, Bing Xu, Qian Zhang

Heliyon. 2024 Mar 30; 10(6): e28127. Published online 2024 Mar 19. doi: 10.1016/j.heliyon.2024.e28127

PMCID:: PMC10963384

Article PDF–3.7M

Select item 621455917.

Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis

Shunsaku Nakagawa, Mayumi Nakaishi, Motomu Hashimoto, Hiromu Ito, Wataru Yamamoto, Ran Nakashima, Masao Tanaka, Takao Fujii, Tomohiro Omura, Satoshi Imai, Takayuki Nakagawa, Atsushi Yonezawa, Hirohisa Imai, Tsuneyo Mimori, Kazuo Matsubara

PLoS One. 2018; 13(11): e0206943. Published online 2018 Nov 2. doi: 10.1371/journal.pone.0206943

PMCID:: PMC6214559

Article PDF–714K

Select item 389529018.

Buparvaquone loaded solid lipid nanoparticles for targeted delivery in theleriosis

Maheshkumar P. Soni, Nilakash Shelkar, Rajiv V. Gaikwad, Geeta R. Vanage, Abdul Samad, Padma V. Devarajan

J Pharm Bioallied Sci. 2014 Jan-Mar; 6(1): 22–30. doi: 10.4103/0975-7406.124309

PMCID:: PMC3895290

Article

Select item 288136119.

Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework

Yoshihiro Yamanishi, Masaaki Kotera, Minoru Kanehisa, Susumu Goto

Bioinformatics. 2010 Jun 15; 26(12): i246–i254. Published online 2010 Jun 1. doi: 10.1093/bioinformatics/btq176

PMCID:: PMC2881361

Article PDF–2.2M

Select item 706887420.

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Yi-Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi, Emi Yamada

Arthritis Res Ther. 2020; 22: 47. Published online 2020 Mar 12. doi: 10.1186/s13075-020-2125-2

Correction in:: Arthritis Res Ther. 2020; 22: 155.

PMCID:: PMC7068874

Article PDF–1.2M

<< First< Prev

Page of 4

Next >Last >>

Supplemental Content

Filter your results:

All (70)
NIH grants (3)
Embargoed (0)

Manage Filters

PMC Images search for Actarit

Fig. 2

Representative HPLC chromatogram of actarit and internal standard Representative HPLC chromatogram of standard solution, showing peaks of actarit (Act) at Rt 4.705 min and internal standard (IS) at Rt 9.055 min

Determination of Actarit from Human Plasma for Bioequivalence Studies

Indian J Pharm Sci. 2010 Nov-Dec;72(6):726-731.
Fig. 1

Chemical structure of actarit

Determination of Actarit from Human Plasma for Bioequivalence Studies

Indian J Pharm Sci. 2010 Nov-Dec;72(6):726-731.
Fig. 4

Representative chromatogram of volunteer plasma sample Representative HPLC chromatograms of study subject plasma sample collected after a single oral administration of 100 mg actarit tablet at-(a) 0 h, (b) 1.5 h showing peaks of actarit (Act) at Rt 4.685 min and internal standard (IS) at 9.073 min and (c) 6 h showing peaks of actarit (Act) at Rt 4.612 min and internal standard (IS) at 9.087 min

Determination of Actarit from Human Plasma for Bioequivalence Studies

Indian J Pharm Sci. 2010 Nov-Dec;72(6):726-731.
Fig. 3

Comparative HPLC Chromatograms Selectivity Representative Chromatograms of (a) Blank plasma chromatogram and (b) Plasma spiked with actarit (Act) at Rt 4.620 min and internal standard (IS) at Rt 9.078 min)

Determination of Actarit from Human Plasma for Bioequivalence Studies

Indian J Pharm Sci. 2010 Nov-Dec;72(6):726-731.